Most health brand founders know that getting listed in Boots or Holland & Barrett is a major milestone. Fewer know what the technical requirements actually look like once you get past the buyer and into the supplier onboarding process.
Both retailers have technical review teams. Both go beyond regulatory minimums. And both are increasingly asking for clinical substantiation for products making specific health claims. This guide explains what to expect and how to prepare.
How retail health product reviews work
When a health product is proposed for ranging, most major retailers follow a two-stage process: a commercial review (margin, price positioning, category fit) and a technical review (claims substantiation, ingredient safety, regulatory compliance). Failing the commercial review loses you the meeting. Failing the technical review loses you the listing after the meeting.
The technical review is where clinical evidence becomes directly relevant. Retailers need to be confident that the claims on your packaging and marketing can be defended, both under ASA rules and under their own due diligence standards.
What Boots requires
Boots operates one of the most rigorous technical review processes among UK health retailers. Their pharmaceutical heritage means the bar for evidence is higher than most brand founders expect when approaching them for the first time.
For products making standard authorised health claims from the GB register, Boots' technical team will verify claim wording and nutrient levels. This is straightforward for brands following the register correctly.
For products making claims beyond the authorised register, such as formula-specific efficacy claims, Boots will ask for the evidence behind those claims. In practice this means:
- A published peer-reviewed study specific to your formula or the key active ingredient at the dose used
- Clear traceability between the study outcomes and the claims on-pack
- Confirmation that the claims comply with ASA/CAP standards
Brands that cannot provide this substantiation typically have two options: remove the unevidenced claims from their packaging, or delay the ranging conversation until the evidence is in place. Arriving with a published study means neither concession is required.
What Holland & Barrett requires
Holland & Barrett has a stated commitment to science-backed products and an internal science team that reviews supplier submissions. Based on supplier feedback and industry observation, their evidence requirements have become more rigorous as regulatory scrutiny of the supplement category has increased.
Holland & Barrett's technical review focuses on:
- Claim substantiation: does the evidence on file support the claims being made, including claims on the website and in marketing?
- Ingredient safety: is the product safe for the intended population at the stated dose?
- Regulatory compliance: are all claims authorised under the GB register or supported by appropriate evidence?
For brands seeking premium placement, featured positions, or own-label discussions, the evidence bar is higher still. Holland & Barrett's own-brand science team has a strong track record of commissioning and citing clinical studies for their formulations, and they expect the same standard from third-party brands they position alongside those products.
A buyer at a major UK health retailer can say yes to a listing in a commercial meeting and no to the same listing six weeks later when their technical team reviews the claims. Arriving with published evidence closes that gap before it opens.
Nathan Phillips, CEO, StudySetGoWhat an evidence dossier looks like
A clinical evidence dossier is the document package you prepare to substantiate your product's health claims. Retailers, buyers, and their technical teams use it to confirm that the claims on your product are defensible.
A well-prepared dossier typically includes:
- Claims summary. A clear list of every health claim made on the product and in marketing, referenced to the evidence supporting each one.
- Published clinical study. The full published paper (or accepted manuscript) for your product's trial. This is the anchor document for all formula-specific claims.
- Study summary for non-technical reviewers. A one-page plain-English summary of the study design, key findings, and the claims it supports. Technical teams are specialists but buyers are not, and both may review your dossier.
- Regulatory claims matrix. Confirmation of which claims are authorised under the GB register, which are supported by the clinical study, and that none cross the MHRA's medicinal claims boundary.
StudySetGo prepares a claims substantiation summary as part of the post-study deliverables, specifically designed to be used in retail buyer submissions.
The commercial argument for going in with evidence
Clinical evidence does not just help you pass technical review. It changes the commercial conversation with the buyer before you even reach that stage.
A published clinical study gives a buyer something they value: a differentiating story for their category. "The only product in this category proven in a clinical trial to improve X" is a shelf message that supports their own commercial objectives. Buyers at specialist health retailers understand this and actively seek products that give them a credible story alongside a strong margin.
Without evidence, the conversation defaults to price, margin, and promotional support. With evidence, the conversation includes product uniqueness, category elevation, and the evidence-based claims that justify a premium price point.
Frequently asked questions
Not for all products. For products making authorised nutrient claims from the GB register, ingredient-level substantiation is generally sufficient. For products making claims about your specific formula's efficacy, both retailers will ask for the published study behind those claims. The higher the claim specificity, the stronger the evidence requirement.
A dossier is a document package that substantiates the health claims on your product. It typically includes a claims summary referenced to the supporting evidence, the published clinical study, a plain-English study summary, and a regulatory compliance matrix. Retail technical teams use it to verify your claims before approving a listing.
Yes, for products making only authorised claims from the GB register. However, without a clinical trial you are limited to claim language that every competitor using the same ingredients can also use. A clinical trial is what makes your product's claims unique and gives you a differentiated story for the buyer conversation.
With StudySetGo, most trials deliver published or accepted manuscript evidence within 6 to 9 months of kick-off. An accepted manuscript (pre-publication) is sufficient for retail buyer dossiers: you do not need to wait for the journal issue. If you have a buyer meeting in 9 months, starting a trial now is achievable. See our full timeline guide.